Search research articles
Contact Us
Filters
Showing results (71-80 of 82) with videos related to
Page
of 9
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
July 21, 2022
Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
Andrew Dj Pearson, Nathalie Gaspar, Katherine Janeway, et al.
The Lancet. Oncology
|
April 3, 2025
New models for the development of and access to CAR T-cell therapies for children and adolescents with cancer: an ACCELERATE multistakeholder analysis
Andrew D J Pearson, Claudia Rossig, Crystal L Mackall, et al.
Neuro-Oncology
|
December 29, 2019
Age and DNA methylation subgroup as potential independent risk factors for treatment stratification in children with atypical teratoid/rhabdoid tumors
Michael C Frühwald, Martin Hasselblatt, Karolina Nemes, et al.
Journal of Neuro-Oncology
|
September 16, 2019
Diagnostics and treatment of diffuse intrinsic pontine glioma: where do we stand?
Fatma E El-Khouly, Sophie E M Veldhuijzen van Zanten, Vicente Santa-Maria Lopez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 8, 2024
Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial
Lucas Moreno, Rebekah Weston, Cormac Owens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 12, 2025
Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial
Juliet C Gray, Rebekah Weston, Cormac Owens, et al.
Nature Medicine
|
March 12, 2024
Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial
Lindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, et al.
Nature Medicine
|
November 18, 2023
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial
Lindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 24, 2025
Paediatric strategy forum for medicinal product development in diffuse midline gliomas in children and adolescents ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
Andrew Dj Pearson, Sabine Mueller, Mariella G Filbin, et al.
Nature Medicine
|
April 16, 2025
Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial
Lindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 82) with videos related to
Sort By:
Page
of 9
European Journal of Cancer (Oxford, England : 1990)
|
July 21, 2022
Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
Andrew Dj Pearson, Nathalie Gaspar, Katherine Janeway, et al.
The Lancet. Oncology
|
April 3, 2025
New models for the development of and access to CAR T-cell therapies for children and adolescents with cancer: an ACCELERATE multistakeholder analysis
Andrew D J Pearson, Claudia Rossig, Crystal L Mackall, et al.
Neuro-Oncology
|
December 29, 2019
Age and DNA methylation subgroup as potential independent risk factors for treatment stratification in children with atypical teratoid/rhabdoid tumors
Michael C Frühwald, Martin Hasselblatt, Karolina Nemes, et al.
Journal of Neuro-Oncology
|
September 16, 2019
Diagnostics and treatment of diffuse intrinsic pontine glioma: where do we stand?
Fatma E El-Khouly, Sophie E M Veldhuijzen van Zanten, Vicente Santa-Maria Lopez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 8, 2024
Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial
Lucas Moreno, Rebekah Weston, Cormac Owens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 12, 2025
Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial
Juliet C Gray, Rebekah Weston, Cormac Owens, et al.
Nature Medicine
|
March 12, 2024
Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial
Lindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, et al.
Nature Medicine
|
November 18, 2023
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial
Lindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 24, 2025
Paediatric strategy forum for medicinal product development in diffuse midline gliomas in children and adolescents ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
Andrew Dj Pearson, Sabine Mueller, Mariella G Filbin, et al.
Nature Medicine
|
April 16, 2025
Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial
Lindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, et al.
Page
of 9